Welcome to our dedicated page for Context Therapeutics news (Ticker: CNTX), a resource for investors and traders seeking the latest updates and insights on Context Therapeutics stock.
Context Therapeutics Inc. (Nasdaq: CNTX) is a Philadelphia-based biopharmaceutical company dedicated to advancing innovative medicines for solid tumors. The company's core mission is to develop novel therapies for hormone-responsive cancers, with a particular focus on female cancers such as breast, ovarian, and endometrial cancer.
Context Therapeutics’ leading clinical candidate is CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody designed to target and engage T-cells in attacking CLDN6-positive tumors. Preclinical studies have shown promising results, with CTIM-76 demonstrating a capability to induce complete tumor regressions across multiple dose levels. The company plans to enroll the first patient in a Phase 1 clinical trial in mid-2024.
In addition to CTIM-76, Context Therapeutics is working on other promising programs, including Apristor (onapristone XR), an investigational drug targeting progesterone receptor-positive (PR+) breast cancer. Up to 70% of breast cancers express progesterone receptors, making Apristor a potential treatment option for a significant number of patients.
In recent news, Context Therapeutics announced encouraging financial results for the first quarter of 2024, including gross proceeds of approximately $100 million from a private placement. These funds are expected to support the company's operations and research endeavors well into 2028. The U.S. Food and Drug Administration (FDA) has also recently cleared Context's Investigational New Drug (IND) application for CTIM-76, a crucial step toward initiating clinical trials.
Context Therapeutics has a strong pipeline and strategic partnerships, including collaborations with Integral Molecular, which supports the development of therapies targeting difficult protein targets. The company’s robust financial guidance and innovative approach position it for significant growth in the biopharmaceutical sector.
Context Therapeutics Inc. (Nasdaq: CNTX) announced that CEO Martin Lehr will present at the Sachs 15th Annual European Life Sciences CEO Forum on March 1-2, 2022, with on-demand viewing available. The company will also engage in one-on-one meetings from February 28 to March 4, 2022. Context focuses on developing small molecule and immunotherapy treatments for breast and gynecological cancers, particularly its lead candidate, ONA-XR, which is undergoing several clinical trials. For more details, visit their website.
Context Therapeutics announced the appointments of Christopher Beck as SVP of Operations and Mark Fletcher, Ph.D. as VP of R&D, effective January 5, 2022. These appointments come as the company approaches pivotal phases in its pipeline, particularly with its lead product candidate ONA-XR for treating women's cancers. The current Head of CMC, Bill Rencher, Ph.D., will transition to an advisory role. The new leadership team aims to advance research and development initiatives within the company, focusing on effective treatments for hormone-driven cancers.
Context Therapeutics (Nasdaq: CNTX), a women's oncology company, announced that CEO Martin Lehr will participate in two upcoming investor conferences in January 2022. The Biotech Showcase™ 2022 conference is set for January 10-12, with Lehr's panel on women's health scheduled for January 12 at 8 a.m. PST. Additionally, Context will present at the Edison Group Open House: Global Healthcare 2022 from January 25-27 and will hold one-on-one meetings. Context is focused on developing treatments for breast and gynecological cancers, with ongoing clinical trials for its lead candidate, ONA-XR.
Context Therapeutics Inc. (Nasdaq: CNTX) announced promising data from the ONAWA trial at the 2021 San Antonio Breast Cancer Symposium. The trial evaluated onapristone extended release (ONA-XR) in postmenopausal women with PR+ early breast cancer. Results indicated a significant decrease in tumor cell proliferation, especially in tumors with high PR expression. Additionally, two other trials on ONA-XR for metastatic breast cancer were presented. The data suggest ONA-XR's potential as a therapeutic option for hormone-driven cancers, with further evaluations planned in 2022.
Context Therapeutics (Nasdaq: CNTX) has successfully closed a private placement, raising approximately $31.25 million by selling 5,000,000 shares of common stock along with 5,000,000 warrants. Each share and warrant were offered at a combined price of $6.25, with a warrant exercise price also set at $6.25 and a term of five and a half years. The proceeds will enhance the company’s oncology treatment initiatives, particularly its lead candidate, ONA-XR, aimed at tackling hormone-driven breast and gynecological cancers.
Context Therapeutics Inc. (Nasdaq: CNTX) announced a $31.25 million private placement and raised $28.75 million from its IPO. The company focuses on developing treatments for breast and gynecological cancers and has initiated patient dosing in a Phase 2 clinical trial targeting ER+, PR+, HER2- metastatic breast cancer. Recent financial results report a net loss of $1.4 million for Q3 2021 and increased R&D and G&A expenses. Context expects its financial resources will sustain operations until 2024, with ongoing clinical trials for its lead candidate, ONA-XR.
Context Therapeutics (Nasdaq: CNTX) announced a private placement, securing approximately $31.25 million from the sale of 5,000,000 shares of common stock and warrants to purchase an additional 5,000,000 shares. Each share and accompanying warrant are priced at $6.25. The placement is set to close on December 6, 2021, subject to usual conditions. The shares and warrants will not be registered under the Securities Act and may not be sold in the U.S. without registration or an exemption. Context is focused on innovating treatments for breast and gynecological cancers.
Context Therapeutics (Nasdaq: CNTX) announced that clinical data for ONA-XR will be presented at the 2021 San Antonio Breast Cancer Symposium from December 7-10, 2021. The presentations will include primary results from the ONAWA trial, focusing on early-stage breast cancer, as well as updates from ongoing trials in metastatic breast cancer. ONA-XR targets progesterone receptor-positive cancers and is currently undergoing multiple Phase 1b and Phase 2 trials. The company aims to highlight the drug's potential impact on treatment outcomes.
Context Therapeutics has appointed Jennifer Minai-Azary as Chief Financial Officer and Alex Levit as Chief Legal Officer, as announced on November 1, 2021. This leadership change follows the company's recent debut on Nasdaq and aims to strengthen its position in developing treatments for hormone-driven women's cancers. Minai-Azary, with over 20 years of experience, previously served as CFO at Millendo Therapeutics, while Levit brings nearly two decades of legal expertise in the biopharma sector. Both executives are expected to drive the company's strategic growth and clinical milestones.
Context Therapeutics has initiated its Phase 2 trial, the SMILE Study, evaluating ONA-XR (onapristone extended release) in combination with fulvestrant for patients suffering from ER-positive, PR-positive, HER2-negative metastatic breast cancer who have previously progressed on endocrine therapies and CDK4/6 inhibitors. The trial aims to enroll up to 39 patients, focusing on overall response rate and other key metrics. The study is designed to explore ONA-XR's effectiveness in overcoming treatment resistance in this patient population.
FAQ
What is the current stock price of Context Therapeutics (CNTX)?
What is the market cap of Context Therapeutics (CNTX)?
What does Context Therapeutics Inc. do?
What is CTIM-76?
What types of cancer is Context Therapeutics targeting with their therapies?
What recent milestones has Context Therapeutics achieved?
When does Context Therapeutics plan to start the Phase 1 trial for CTIM-76?
What are the financial prospects for Context Therapeutics?
Who are some of Context Therapeutics' strategic partners?
What regulatory approvals has Context Therapeutics received recently?
Where is Context Therapeutics headquartered?
What is Apristor?
